Amgen Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Amgen Inc. stock analysis AMGN overview
Somewhat Bearish -25

Amgen faces Delaware patent verdict, shares under legal scrutiny - Ad-hoc-news.de

🏛️ A Delaware jury found Amgen willfully infringed Harbour BioMed's Grosveld antibody patent in June 2026.

💰 The court awarded Harbour BioMed exactly $20,203,704 in damages for the infringement.

⚖️ Analysts warn that US law permits enhancing the damage award up to three times due to willful infringement.

📉 Legal disputes over platform technologies are now flagged as a key risk factor for Amgen's stock.

💼 The majority of analysts still rate Amgen as Buy or Overweight despite the legal verdict.

📈 Analyst consensus shows double-digit expected earnings per share for the current fiscal year.

💊 Amgen generates revenue from mature therapies including Neulasta, Prolia, and Repatha.

📊 Shares traded at approximately $305 with a market cap of $164 billion as of June 2026.

🎯 The average 12-month price target among analysts is in the low $300 range.

Bullish Signals
  • Majority of analysts maintain Buy or Overweight ratings on Amgen despite recent legal losses.
  • Company maintains double-digit expected earnings per share for the current fiscal year.
  • Amgen holds a strong market position with stable revenue from mature oncology and bone health drugs.
  • Shares traded at $305, indicating sustained investor interest in the biotech giant.
  • Market cap of $164 billion reflects its status as a large-cap S&P 500 leader.
Risk Factors
  • Jury found willful infringement of Harbour BioMed's patent, exposing Amgen to potential enhanced damages up to three times the initial award.
  • Analysts are explicitly flagging litigation and patent challenges as a key risk factor for the stock.
  • The legal verdict forces a reassessment of Amgen's intellectual property risk profile and long-term pipeline valuations.
  • Legal disputes over platform technologies could negatively impact collaboration economics with partners.
Full Analysis
Amgen Inc. faces a significant legal setback after a Delaware federal jury ruled in June 2026 that the company willfully infringed on Harbour BioMed's Grosveld patent regarding antibody technology. The jury awarded Harbour BioMed exactly $20,203,704 in damages, with analysts noting that US law allows for potential enhancement of this award up to three times due to the finding of willful infringement. This verdict has shifted analyst sentiment toward a reassessment of Amgen's intellectual property risk profile. While the majority of Wall Street analysts still maintain Buy or Overweight ratings, citing stable earnings from mature therapies and double-digit expected EPS, litigation over platform technologies is now explicitly flagged as a key risk factor affecting collaboration economics and long-term pipeline valuations. Amgen remains a large-cap biotechnology leader in the S&P 500, generating revenue primarily from oncology, inflammation, and bone health drugs such as Neulasta, Prolia, and Repatha. As of June 2026, shares traded around $305 with a market capitalization of approximately $164 billion. Analyst consensus data suggests an average 12-month price target in the low $300 range, reflecting expectations for continued earnings contributions despite the legal headwind.